171 related articles for article (PubMed ID: 34796520)
1. Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma.
Zhou X; Ruckdeschel A; Peter J; Böckle D; Hornburger H; Danhof S; Steinhardt MJ; Heimeshoff L; Einsele H; Kortüm KM; Rasche L
Hematol Oncol; 2022 Apr; 40(2):202-211. PubMed ID: 34796520
[TBL] [Abstract][Full Text] [Related]
2. Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma.
Zhou X; Steinhardt MJ; Grathwohl D; Meckel K; Nickel K; Leicht HB; Krummenast F; Einsele H; Rasche L; Kortüm KM
Cancer Med; 2020 Aug; 9(16):5819-5826. PubMed ID: 32608149
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
4. Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis.
Stork M; Spicka I; Radocha J; Minarik J; Jelinek T; Jungova A; Pavlicek P; Pospisilova L; Sedlak F; Straub J; Pika T; Knechtova Z; Fidrichova A; Boichuk I; Sevcikova S; Maisnar V; Hajek R; Pour L
Ann Hematol; 2023 Jun; 102(6):1501-1511. PubMed ID: 37088816
[TBL] [Abstract][Full Text] [Related]
5. Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye.
Tekinalp A; Gedük A; Akdeniz A; Terzi Demirsoy E; Gürsoy V; Aslaner Ak M; Bağcı M; Seçilmiş S; Keklik Karadağ F; Oruç Uysal A; Doğan A; Demircioğlu S; Erol HA; Aslan C; Özkalemkaş F; Ertop Ş; Dağlı M; Dal MS; Saydam G; Merter M; Ural C; Çeneli Ö
Turk J Haematol; 2023 Dec; 40(4):242-250. PubMed ID: 37961952
[TBL] [Abstract][Full Text] [Related]
6. DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma.
Goldsmith SR; Fiala MA; Wang B; Schroeder MA; Wildes TM; Ghobadi A; Stockerl-Goldstein K; Vij R
Ann Hematol; 2020 May; 99(5):1041-1048. PubMed ID: 32130471
[TBL] [Abstract][Full Text] [Related]
7. Daratumumab therapy for relapsed or refractory multiple myeloma: a single-center retrospective study.
Sunami K; Murakami H; Tagashira H; Ueda H; Moriyama T; Ishikawa T; Yoshioka T; Makita M
Int J Clin Oncol; 2020 Dec; 25(12):2151-2157. PubMed ID: 32715356
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials.
Lakshman A; Abeykoon JP; Kumar SK; Rajkumar SV; Dingli D; Buadi FK; Gonsalves WI; Leung N; Dispenzieri A; Kourelis TV; Go RS; Lacy MQ; Hobbs MA; Lin Y; Warsame R; Lust J; Fonder AL; Hwa YL; Hayman SR; Russell SJ; Kyle RA; Gertz MA; Kapoor P
Am J Hematol; 2017 Nov; 92(11):1146-1155. PubMed ID: 28799231
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Vozella F; Siniscalchi A; Rizzo M; Za T; Antolino G; Coppetelli U; Piciocchi A; Andriani A; Annibali O; De Rosa L; Cimino G; La Verde G; De Stefano V; Cantonetti M; di Toritto TC; Petrucci MT
Ann Hematol; 2021 Apr; 100(4):1059-1063. PubMed ID: 33528611
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma.
Lakshman A; Singh PP; Rajkumar SV; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Dingli D; Hwa YL; Fonder AL; Hobbs M; Hayman SR; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Lin Y; Gonsalves WI; Kourelis T; Warsame R; Kyle RA; Kumar SK
Am J Hematol; 2018 Feb; 93(2):179-186. PubMed ID: 29067723
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of VD-PACE With Immunomodulatory Agent as a Salvage Therapy for Relapsed/Refractory Multiple Myeloma.
Abdallah AO; Sigle M; Mohyuddin GR; Coggins E; Remker C; Shune L; Mahmoudjafari Z; McGuirk J; Ganguly S
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e220-e226. PubMed ID: 33093009
[TBL] [Abstract][Full Text] [Related]
12. VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience.
Ghandili S; Alihodzic D; Wiessner C; Bokemeyer C; Weisel K; Leypoldt LB
Ann Hematol; 2023 Jan; 102(1):117-124. PubMed ID: 36383242
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
Pelligra CG; Parikh K; Guo S; Chandler C; Mouro J; Abouzaid S; Ailawadhi S
Clin Ther; 2017 Oct; 39(10):1986-2005.e5. PubMed ID: 28967482
[TBL] [Abstract][Full Text] [Related]
14. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
Chari A; Cornell RF; Gasparetto C; Karanes C; Matous JV; Niesvizky R; Lunning M; Usmani SZ; Anderson LD; Chhabra S; Girnius S; Shustik C; Stuart R; Lee Y; Salman Z; Liu E; Valent J
Hematol Oncol; 2020 Aug; 38(3):353-362. PubMed ID: 32053229
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study.
Iida S; Ishikawa T; Min CK; Kim K; Yeh SP; Usmani SZ; Mateos MV; Nahi H; Heuck C; Qin X; Parasrampuria DA; Gries KS; Qi M; Bahlis N; Ito S
Ann Hematol; 2021 Apr; 100(4):1065-1077. PubMed ID: 33599794
[TBL] [Abstract][Full Text] [Related]
16. Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.
Derman BA; Zonder J; Reece D; Cole C; Berdeja J; Stefka AT; Major A; Kin A; Griffith K; Jasielec J; Jakubowiak AJ
Blood Adv; 2023 Oct; 7(19):5703-5712. PubMed ID: 36763537
[TBL] [Abstract][Full Text] [Related]
17. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
Mele A; Prete E; De Risi C; Citiso S; Greco G; Falcone AP; Sanpaolo G; Mele G; Giannotta A; Vergine C; Reddiconto G; Palazzo G; Sabatelli S; Germano C; Miccolis R; Curci P; Palumbo G; Offidani M; Rizzi R; Cascavilla N; Pastore D; Di Renzo N; Mazza P; Tarantini G; Guarini A; Capalbo S; Specchia G; Greco A; De Francesco R; Sibilla S; Tonialini L; Morciano MR; Pavone V
Ann Hematol; 2021 Feb; 100(2):429-436. PubMed ID: 33161453
[TBL] [Abstract][Full Text] [Related]
18. A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.
Du J; Fang B; Li J; Jin J; Wang S; Zou D; Cai Z; Wang H; Hu J; Li W; Fu C; Shao Z; Xia Z; Liu P; Niu T; Tang ET; Kimball AS; Hou J; Chen W
Int J Hematol; 2021 Mar; 113(3):422-429. PubMed ID: 33389656
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma.
Abdallah AO; Mohyuddin GR; Mahmoudjafari Z; Atrash S; Kawsar H; Sigle M; Shune L; McGuirk J; Ganguly S
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e212-e219. PubMed ID: 33051166
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Chari A; Martinez-Lopez J; Mateos MV; Bladé J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A; de Boer C; Wang J; Clemens PL; Ukropec J; Schecter J; Lonial S; Moreau P
Blood; 2019 Aug; 134(5):421-431. PubMed ID: 31113777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
